These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 37335589)

  • 1. A Multicenter Phase II Study Evaluating the Safety and Efficacy of Botulax in Asian Patients with Benign Masseteric Hypertrophy.
    Lee JS; Son HS; Kim BJ; Lee YW
    Plast Reconstr Surg; 2024 May; 153(5):910e-918e. PubMed ID: 37335589
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and Safety of a Novel Botulinum Toxin A for Masseter Reduction: A Randomized, Double-Blind, Placebo-Controlled, Optimal Dose-Finding Study.
    Hong JY; Jeong GJ; Kwon TR; Kim JH; Li K; Kim BJ
    Dermatol Surg; 2021 Jan; 47(1):e5-e9. PubMed ID: 33347002
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and Safety of PrabotulinumtoxinA in Subjects With Benign Masseteric Hypertrophy: A Double-Blind, Randomized, Placebo-Controlled, Multicenter, Phase 3 Trial and Open-Label Extension Study.
    Seok J; Koh YG; Hong JK; Yun SH; Kim DH; Son HS; Choi SY; Yoo KH; Lee YW; Kim BJ
    Dermatol Surg; 2024 Jun; 50(6):527-533. PubMed ID: 38518110
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy of Botulinum Toxin in Treating Asian Indian Patients with Masseter Hypertrophy: A 4-Year Follow-Up Study.
    Shome D; Khare S; Kapoor R
    Plast Reconstr Surg; 2019 Sep; 144(3):390e-396e. PubMed ID: 31461011
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Classification of masseter hypertrophy for tailored botulinum toxin type A treatment.
    Xie Y; Zhou J; Li H; Cheng C; Herrler T; Li Q
    Plast Reconstr Surg; 2014 Aug; 134(2):209e-218e. PubMed ID: 25068343
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Abobotulinum toxin A and onabotulinum toxin A for masseteric hypertrophy: a split-face study in 25 Korean patients.
    Lee SH; Wee SH; Kim HJ; Yeo UC; Lee NH; Lee SW; Cho SB
    J Dermatolog Treat; 2013 Apr; 24(2):133-6. PubMed ID: 21888570
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Botulinum toxin type A treatment for contouring of the lower face.
    Park MY; Ahn KY; Jung DS
    Dermatol Surg; 2003 May; 29(5):477-83; discussion 483. PubMed ID: 12752514
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of botulinum toxin type A on contouring of the lower face.
    Choe SW; Cho WI; Lee CK; Seo SJ
    Dermatol Surg; 2005 May; 31(5):502-7; discussion 507-8. PubMed ID: 15962731
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Does Botulinum Toxin Injection into Masseter Muscles Affect Subcutaneous Thickness?
    Park G; Choi YC; Bae JH; Kim ST
    Aesthet Surg J; 2018 Feb; 38(2):192-198. PubMed ID: 29117291
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Literature review of the adverse events associated with botulinum toxin injection for the masseter muscle hypertrophy.
    Yeh YT; Peng JH; Peng HP
    J Cosmet Dermatol; 2018 Oct; 17(5):675-687. PubMed ID: 30091170
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Botulinum Toxin Injections for Masseter Reduction in East Asians.
    Cheng J; Hsu SH; McGee JS
    Dermatol Surg; 2019 Apr; 45(4):566-572. PubMed ID: 30883483
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Temporal volume increase after reduction of masseteric hypertrophy utilizing incobotulinumtoxin type A.
    Nikolis A; Enright KM; Rudolph C; Cotofana S
    J Cosmet Dermatol; 2020 Jun; 19(6):1294-1300. PubMed ID: 32338450
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Exploring botulinum toxin's impact on masseter hypertrophy: a randomized, triple-blinded clinical trial.
    de Souza Nobre BB; Rezende L; Barbosa Câmara-Souza M; Sanchez-Ayala A; Blass R; Carbone AC; Manso AC; Ernberg M; Christidis N; De la Torre Canales G
    Sci Rep; 2024 Jun; 14(1):14522. PubMed ID: 38914688
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of botulinum toxin type A on bilateral masseteric hypertrophy evaluated with computed tomographic measurement.
    Kim HJ; Yum KW; Lee SS; Heo MS; Seo K
    Dermatol Surg; 2003 May; 29(5):484-9. PubMed ID: 12752515
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of incobotulinum toxin A in periocular rhytides and masseteric hypertrophy: side-by-side comparison with onabotulinum toxin A.
    Lee JH; Park JH; Lee SK; Han KH; Kim SD; Yoon CS; Park JY; Lee JH; Yang JM; Lee JH
    J Dermatolog Treat; 2014 Aug; 25(4):326-30. PubMed ID: 23356833
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Botulinum toxin type A for the treatment of hypertrophy of the masseter muscle.
    Kim NH; Park RH; Park JB
    Plast Reconstr Surg; 2010 Jun; 125(6):1693-1705. PubMed ID: 20517093
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The change of maximum bite force after botulinum toxin type a injection for treating masseteric hypertrophy.
    Ahn KY; Kim ST
    Plast Reconstr Surg; 2007 Nov; 120(6):1662-1666. PubMed ID: 18040203
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Botulinum toxin a for lower facial contouring: a prospective study.
    Yu CC; Chen PK; Chen YR
    Aesthetic Plast Surg; 2007; 31(5):445-51; discussion 452-3. PubMed ID: 17674088
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Botulinum Toxin Injection Technique for Reducing the Masseter Size and Enhancing the Jawline.
    Zhuang J; Jiang L; Zhou Y; Wang C; Chen Y; Su X; Wei Q; Zhang Z; Hu J
    Aesthet Surg J; 2024 Jul; 44(8):NP567-NP573. PubMed ID: 38494986
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of two different units of botulinum toxin type a evaluated by computed tomography and electromyographic measurements of human masseter muscle.
    Kim JH; Shin JH; Kim ST; Kim CY
    Plast Reconstr Surg; 2007 Feb; 119(2):711-7. PubMed ID: 17230111
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.